JP2009215293A5 - - Google Patents

Download PDF

Info

Publication number
JP2009215293A5
JP2009215293A5 JP2009052853A JP2009052853A JP2009215293A5 JP 2009215293 A5 JP2009215293 A5 JP 2009215293A5 JP 2009052853 A JP2009052853 A JP 2009052853A JP 2009052853 A JP2009052853 A JP 2009052853A JP 2009215293 A5 JP2009215293 A5 JP 2009215293A5
Authority
JP
Japan
Prior art keywords
ziprasidone
dosage form
oral dosage
solid oral
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009052853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009215293A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009215293A publication Critical patent/JP2009215293A/ja
Publication of JP2009215293A5 publication Critical patent/JP2009215293A5/ja
Withdrawn legal-status Critical Current

Links

JP2009052853A 2008-03-07 2009-03-06 食物なしでジプラシドンを投与するための方法、剤形、およびキット Withdrawn JP2009215293A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3494708P 2008-03-07 2008-03-07

Publications (2)

Publication Number Publication Date
JP2009215293A JP2009215293A (ja) 2009-09-24
JP2009215293A5 true JP2009215293A5 (enExample) 2012-04-12

Family

ID=40720011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009052853A Withdrawn JP2009215293A (ja) 2008-03-07 2009-03-06 食物なしでジプラシドンを投与するための方法、剤形、およびキット

Country Status (15)

Country Link
US (1) US20110002989A1 (enExample)
EP (1) EP2280711A1 (enExample)
JP (1) JP2009215293A (enExample)
KR (1) KR20100131477A (enExample)
CN (1) CN102014910A (enExample)
AR (1) AR070964A1 (enExample)
AU (1) AU2009220925A1 (enExample)
BR (1) BRPI0909818A2 (enExample)
CA (1) CA2719115A1 (enExample)
IL (1) IL207792A0 (enExample)
MX (1) MX2010009844A (enExample)
RU (1) RU2010135831A (enExample)
TW (1) TW200950783A (enExample)
WO (1) WO2009109844A1 (enExample)
ZA (1) ZA201005905B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US9510148B2 (en) * 2009-03-03 2016-11-29 Mobilitie, Llc System and method for wireless communication to permit audience participation
JP2016522188A (ja) * 2013-05-03 2016-07-28 シンダックス ファーマシューティカルズ,インク. 癌の処置方法
EP3027171B1 (en) 2013-07-30 2020-03-25 Gilead Connecticut, Inc. Formulation of syk inhibitors
EA201791873A1 (ru) 2013-07-30 2018-09-28 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
KR20160093611A (ko) * 2013-12-05 2016-08-08 알라이즈 바이오시스템즈 게엠베하 경구 투여를 위한 약물 제제의 제조 방법
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US10474345B2 (en) * 2014-04-04 2019-11-12 Shawn SHEY User interfaces and methods for displaying content
BR112017005283A2 (pt) * 2014-09-19 2017-12-12 Procter & Gamble processo para produção de um núcleo com um revestimento ativo
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US11154510B2 (en) 2015-06-11 2021-10-26 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN107714669A (zh) * 2016-08-11 2018-02-23 广东东阳光药业有限公司 齐拉西酮缓释剂及其制备方法
CN111051311A (zh) 2017-08-25 2020-04-21 吉利德科学公司 Syk抑制剂的多晶型物
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
AR046811A1 (es) * 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
SG162811A1 (en) * 2005-06-20 2010-07-29 Elan Pharma Int Ltd Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds

Similar Documents

Publication Publication Date Title
JP2009215293A5 (enExample)
RU2010135831A (ru) Способы, лекарственные формы и наборы для введения зипрасидона без пищи
JP2014528474A5 (enExample)
JP2017128614A5 (enExample)
JP2019517542A5 (enExample)
JP2019507797A5 (enExample)
RU2019134558A (ru) Композиции и способы лечения анемии
AU2013205648A1 (en) Combination treatment
CN103096878B (zh) 包含苯并咪唑衍生物的固体药物组合物
DK2900230T3 (en) RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
JP2018505158A5 (enExample)
JP2016516016A5 (enExample)
JP2020530831A5 (enExample)
JP2015515984A5 (enExample)
JP2019529570A5 (enExample)
JP2020500864A5 (enExample)
JP2007500176A5 (enExample)
JP2019534330A5 (enExample)
WO2020069288A1 (en) Grapiprant unit dosage forms
JP2016512247A5 (enExample)
KR20160011205A (ko) 히드로코티손을 포함하는 조성물
CN105919979A (zh) 一种替曲朵辛肠溶缓释微丸、制备方法及其应用
JP2018505901A5 (enExample)
CN102485228B (zh) 一种药物组合物及其用途
CN105106243A (zh) Bacteroides thetaiotaomicron VPI-5482在制备治疗或预防肥胖症药物中的应用